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Background: Methamphetamine (meth) dependence presents a substantial socioeconomic burden. Despite the
need, there is no FDA-approved pharmacotherapy for psychostimulant dependence. We consider 5-HT2C receptors
as viable therapeutic targets. We recently revealed that the atypical antidepressant, mirtazapine, attenuates
meth-seeking in a rodent model of human substance abuse. Mirtazapine historically has been considered to be an
antagonist at 5-HT2C receptors, but more recently shown to exhibit inverse agonism at constitutively active 5-HT2C
receptors. To help distinguish the roles for antagonism vs. inverse agonism, here we explored the ability of a more
selective 5-HT2C inverse agonist, SB 206553 to attenuate meth-seeking behavior, and compared its effects to those
obtained with 5-HT2C antagonists, SDZ Ser 082 and SB 242084. To do so, rats were trained to self-administer meth
and tested for seeking-like behavior in cue reactivity sessions consisting of contingently presenting meth-associated
cues without meth reinforcement. We also explored motor function to determine the influence of SB 206553 and
SDZ Ser 082 on motor activity in the presence and absence of meth.
Results: Like mirtazapine, pretreatment with SB 206553 (1.0, 5.0, and 10.0 mg/kg), attenuated meth-seeking. In
contrast, the antagonists, SDZ Ser 082 (0.1, 0.3, and 1.0 mg/kg) and SB 242084 (3.0 mg/kg) had no effect on cue
reactivity (CR). SB 242084 (3.0 mg/kg) failed to attenuate the effects of 5.0 and 10 mg/kg SB 206553 on CR. Motor
function was largely unaltered by the 5-HT2C ligands; however, SB 206553, at the highest dose tested (10.0 mg/kg),
attenuated meth-induced rearing behavior.
Conclusions: The lack of effect by 5-HT2C antagonists suggests that meth-seeking and meth-evoked motor activity
are independent of endogenous 5-HT acting at 5-HT2C receptors. While SB 206553 dramatically impacted
meth-evoked behaviors it is unclear whether the observed effects were 5-HT2C receptor mediated. Thus, SB 206553
deserves further attention in the study of psychostimulant abuse disorders.
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Psychostimulants such as cocaine and methamphetamine
(meth) dramatically enhance transmission of monoa-
mines, including serotonin (5-HT). It is clear that the
5-HT2C receptor subtype is involved in stimulant-mediated
behaviors [1,2]. For example, 5-HT2C receptor agonists de-
crease cue-induced reinstatement of cocaine-seeking [3-6]
(5-HT2C antagonists have no effect [5,7]). These latter
findings suggest that cue-associated seeking behavior* Correspondence: Steven_Graves@rush.edu
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distribution, and reproduction in any mediumis not dependent on 5-HT levels at synapses expressing
5-HT2C receptors (illustrated by the lack of effect of
antagonists on cocaine cue-induced reinstatement);
nonetheless, the systems regulating seeking behavior are
under negative control by activated 5-HT2C receptors
(illustrated by the ability of 5-HT2C agonists to decrease
cue-induced reinstatement of cocaine-seeking). The ma-
jority of behavioral studies focusing on 5-HT2C receptors
have relied on agonist/antagonist relationships. However,
evidence indicates constitutive activity (i.e. agonist-
independent activation) of 5-HT2C receptors in vivo [8-10]
and it currently is unknown how constitutively active
5-HT2C receptors impact stimulant-induced behaviors.
5-HT2C receptors are the only known G protein
coupled receptor to undergo mRNA editing by adenosineentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 5-HT2C receptors
5-HT2A 5-HT2B 5-HT2C
SDZ Ser 082 6.3 6.7 8.1
SB 242084 6.1 6.8 8.2
SB 206553 5.6 7.7 7.8
pKi values (nM) for 5-HT2 receptor ligands in HEK-293 or CHO-K1 cells
expressing human recombinant 5-HT2 receptors [45].
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cations for the level of constitutive activity. Adenosine
to inosine switches result in amino acid substitutions in
the second intracellular loop of the receptor protein
[13-15]. The unedited 5-HT2C receptor displays high
levels of constitutive activity [16-20], and these receptor
protein substitutions decrease constitutive activity. Con-
stitutive activity can be attenuated pharmacologically by
inverse agonists, these drugs stabilize the receptor in its
inactive conformation [21,22]. For example, systemic
administration of the 5-HT2C inverse agonist SB 206553
(SB206) enhances dopamine (DA) efflux in the nucleus
accumbens and striatum in rats [8], whereas an agonist
either decreases or has no effect on accumbal and stri-
atal DA [8,23-27]. Supporting a role of constitutive ac-
tivity in this effect, the SB206-induced effects were
verified to occur independent of endogenous 5-HT [8].
We previously revealed that the atypical antidepressant,
mirtazapine, attenuates methamphetamine (meth)-
induced sensitization [28], place conditioning [29-31],
and seeking [31] in rodent models of human substance
abuse. Mirtazapine historically has been considered to
be an antagonist at 5-HT2C and other receptors [32-34];
however, more recent studies indicate its action as an
inverse agonist at constitutively active 5-HT2C receptors
[35,36]. These new observations raised the following
questions: Would a more selective 5-HT2C receptor in-
verse agonist, like mirtazapine, also reduce meth-seeking?
A related question is whether seeking for meth is similar
to, or differs from, that for cocaine with regard to sensiti-
vity to selective 5-HT2C inverse agonists and/or
antagonists?
To answer the above questions, we used two 5-HT2C
antagonists of different chemical structures, SB 242084
(SB242) and SDZ Ser 082 (SDZ) as well as the putative
5-HT2C receptor inverse agonist SB206. Dose–response
evaluations on meth-seeking behaviors were made for
these drugs in using cue reactivity (CR) to meth-
associated cues established during a self-administration
protocol. We have previously demonstrated that CR
offers an effective means to study drug-seeking that, as
is more typical in the human scenario, does not depend
on prior extinction training [31]. We also revealed that
the ability of mirtazapine to alter seeking behavior is
similar for CR and cue-induced reinstatement (following
extinction) protocols [37]. Finally, to ascertain whether
5-HT2C receptor compounds influenced motor activity,
rats tested for CR also underwent motor assessments
with acute 5-HT2C ligand pretreatment.
Methods
Subjects
Fifty male Sprague–Dawley rats were purchased from
Harlan (Indianapolis, IN), acclimated to housing in ourlocal vivarium for 5 days, and handled a minimum of 3
times prior to surgery. Food and water were provided ad
libitum throughout the study. Rats were maintained in ac-
cordance with the Guide for Care and Use of Laboratory
Animals (National Research Council, Washington DC)
and with the guidelines and approval of the Rush Univer-
sity Institutional Animal Care and Use Committee.Drugs
(+)-Methamphetamine HCl (Sigma, St. Louis, MO)
was dissolved in sterile saline. The stimulant was self-
administered at 0.1 mg/kg/0.1 mL infusion intravenously
(iv) and non-contingently administered intraperitoneally
(ip) for motor assessments as 1.0 mg/kg. SDZ Ser 082
(SDZ; Tocris, Ellisville, MO), a 5-HT2C antagonist, was
dissolved in saline and injected ip (0.1, 0.3, and
1.0 mg/kg). SB 242084 (SB242; Tocris), also a 5-HT2C
antagonist, was dissolved in 8 % β-cyclodextran and 1 %
citric acid in deionized water and injected ip (3.0 mg/kg).
SB 206553 (SB206) (Tocris), a 5-HT2C inverse agonist,
was dissolved in 1 % lactic acid in deionized water and
injected ip (1.0, 5.0, and 10.0 mg/kg). Serotonin2C ligands
were administered in volumes of 1.0 ml/kg with the ex-
ception of 10.0 mg/kg SB206, which was administered at
2 ml/kg (from a 5.0 mg/ml stock solution). All drugs
were administered as the base. pKi values of SDZ, SB242
and SB206 for 5-HT2 receptor subtypes are provided in
Table 1.Surgical procedures
Rats were instrumented with a jugular vein catheter
under continuous isoflurane anesthesia. Custom built
catheters were constructed with silastic tubing (0.3 mm
i.d. x 0.64 mm o.d.; Dow Corning Co., Midland, MI) and
implanted into the right jugular vein. The distal end of
the catheter extended to the mid-scapular region with a
metal guide canulae (22 gauge; Plastics One Inc., Roanoke,
VA) and anchored to a plastic mesh. Rats were allowed
to recover for a minimum of 5 days prior to beginning
self-administration procedures. During this time, rats
were handled, inspected and weighed daily to ensure
that surgical wounds were healing properly (without in-
fection), that normal behavioral grooming/eating pat-
terns were retained, and that preoperative weight was
regained.
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Rats were trained to self-administer meth 3 hr/day for
14 consecutive days in standard operant chambers
enclosed in ventilated, sound attenuating cabinets (Med-
Associates, St. Albans, VT). Each operant chamber con-
tained two levers; the left lever assigned as the “active”
lever and the right the “inactive” lever. Above each lever
was a cue light and located on the opposite wall was an
in-house light. A cue light above the active lever was
activated in association with the infusion pump and the
in-house light was subsequently activated for 20s, indi-
cating a time-out period during which responses had no
programmed consequences. Responding on the inactive
lever also had no programmed consequences. On days
1–7, rats self-administered meth for 3 hr/day on a fixed
ratio (FR) 1 schedule of reinforcement. On days 8–14,
rats self-administered on a FR5 for 3 hr/day (refer to
Figure 1) to enhance lever pressing behaviors and resist-
ance to extinction [38]. Starting on day 8, rats were
acclimated to injection procedures via daily ip vehicle
pretreatments (30 min). The number of active lever
presses, inactive lever presses, and infusions were
recorded for all sessions. Stable self-administration be-
havior was operationally defined as <15 % infusion vari-
ability between days 13 and 14; failure to reach this
criterion resulted in subject exclusion from the study.Cue reactivity testing
Meth-seeking behavior was assessed via CR tests. CR
testing consisted of single, 1 hr extinction sessions during
which cues (i.e., cue light, time-out house light, and acti-
vation of infusion pump) were contingently presented on
an FR1 schedule. During CR tests, infusion lines were
filled with sterile saline and remained connected to
saline-filled syringes (syringes were disconnected fromFigure 1 Timeline of experimental protocol. Rats self-administered
methamphetamine (meth) for 14 consecutive days (3 hrs/day). Days (D)
1–7 a fixed ratio (FR) 1 schedule of reinforcement was used for training.
To increase responding rates, an FR5 was employed for days 8–14. On
day 15, rats were acclimated to the cue reactivity (CR) protocol.
Assessments of 5-HT2C ligands on meth-seeking were made days 18, 21,
24, and 27 (i.e., CR2-CR5); treatments for CR were randomized. Between
each CR test, rats were allowed to self-administer meth for two
consecutive days on an FR5 schedule (3 hrs/day). Five days after CR5 (on
day 33), motor assessments were initiated.pumps to prevent excessive fluid intake). Meth was not
accessible during CR testing. The number of active and
inactive lever presses was measured continuously and
tallied in 15 min intervals. On day 15, rats were given
a 30 min pretreatment of vehicle and tested for base-
line meth-seeking (CR1); baseline was used to equally
distribute rats into treatment groups. Rats were tested
for an additional four CR tests (CR2-5); between each
CR test, rats were allowed to self-administer meth for
3 hr/day on an FR5 schedule (referred to as intermittent
self-administration; see Figure 1) to prevent extinction
training. Rats failing to administer at least 50 % of the
number of infusions administered on day 14, for two con-
secutive days during intermittent self-administration ses-
sions, were removed from the study. Rats were tested for
CR after a 30 min pretreatment of 0.1, 0.3, 1.0 mg/kg SDZ
and vehicle (treatment group 1) or 1.0, 5.0, 10.0 mg/kg
SB206, and vehicle (group 2). The 5-HT2C receptor an-
tagonist, SB242, was tested against the 5-HT2C receptor
inverse agonist SB206 in the same rats, wherein SB242
(3.0 mg/kg ip) was administered 45 min, and SB206 (5.0
or 10.0 mg/kg ip) was administered 30 min, prior to the
onset of CR testing. Dose order was randomized for all
treatment groups. Doses of SB206 and SB242 were
guided by literature demonstrating significant neuro-
chemical effects in the nucleus accumbens [8]. Doses of
SDZ were selected based on reports revealing an en-
hancement of the interoceptive cues of cocaine [39] and
cocaine-evoked motor activity in naïve rats [40]. We
have previously shown that the described CR paradigm
is comparable to cue-induced reinstatement and that
pharmacological intervention paradigms similar to those
tested in the current report similarly reduce CR and
cue-induced reinstatement [37]. Assessments were made
at an early stage of withdrawal (24 hr) based on our
aforementioned work [37] as well as evidence indicating
that psychostimulant administration dysregulates neur-
onal function in the nucleus accumbens shell (a region
with constitutively active 5-HT2C receptors [10]) as early
as 1–3 days of withdrawal [41] as well as biochemical in-
dices indicating psychostimulant-induced plasticity in
multiple brain regions during early phase withdrawal
(1–3 days) using place conditioning paradigms [42,43]
and motor sensitization [44].
Motor assessments
A subset of rats tested for CR dose–response assess-
ments was used to determine the motor effects of SDZ
(1.0 mg/kg ip) and SB206 (5.0 and 10.0 mg/kg ip) in the
presence and absence of meth (1.0 mg/kg ip). For this
study, rats were withdrawn from meth and remained in
their home cages during protocol days 28–32 and
received no treatment (refer to Figure 1). After this
5 day period, rats were tested for motor activity for 3
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were conducted using automated small animal activity
boxes (Accuscan Instruments, Columbus, OH) equipped
with two banks of photobeams positioned at different
heights to characterize motor activity in three dimen-
sional space. Rats were habituated to activity chambers
for 1 hr prior to each motor test. On day 33, rats were
administered 1 ml/kg of the respective vehicle for each
test drug (rats for effects of SDZ were administered sa-
line and rats tested for SB206-induced effects were
administered 1 % lactic acid in deionized water). The
injected rats were immediately returned to motor boxes
for 1 hr after which rats were injected with either SDZ
(1.0 mg/kg), or SB206 (5.0 or 10.0 mg/kg) and behavior
was recorded for an additional 1 hr. Motor data col-
lected 30 min post-injection were subsequently analyzed;
this time frame reflected the one that was relevant to CR
behaviors. On day 34, rats were administered a 30 min
pretreatment of vehicle (saline or 1 % lactic acid), then
administered 1 mg/kg meth (ip) and behavior recorded
for 1 hr. On day 35, the procedure from day 34 was
repeated using SDZ (1.0 mg/kg), or SB206 (5.0 or
10.0 mg/kg) (ip) instead of respective vehicles. Peak
meth effects occurred 15 min post meth injection; meth-
evoked motor activity was therefore analyzed for the last
45 min of testing (i.e., 15 min post meth injection).
Horizontal activity (number of beam breaks in the hori-
zontal plane), vertical activity (number of beam breaks
in the vertical plane indicating rearing-like behavior),
and total distance (cm traversed within the chamber)
were recorded. These assessments provide a reliable
index of overall motor patterns evoked by this dose of
meth [28]. Stereotypy (rapid, repetitive behaviors) is a
prominent component of meth-induced motor activity
[28]; therefore, stereotypy number (the number of beam
breaks repetitively disrupted) also was analyzed for
meth-evoked motor activity. Rats tested for effects of
SDZ on motor function were also tested for SDZ effects
on CR; similarly, rats tested for effects of SB206 on
motor function had prior exposure to SB206 during CR
assessments.
Statistical analysis
Active lever presses, inactive lever presses, and number
of infusions achieved during self-administration sessions
were analyzed using a one-way rmANOVA with
Newman-Keuls post-hoc analysis. The differences in
lever pressing during CR tests were detected using two-
way rmANOVA with Newman-Keuls post-hoc analysis.
Lever pressing behavior for days 16 and 26 of intermit-
tent self-administration, and motor activity were ana-
lyzed using a paired t-test. For all tests, α= 0.05. Data
are presented as mean± SEM. Data greater than two
standard deviations from the mean were considered tobe statistical outliers and were excluded from the ana-
lyses; for CR, outliers were determined from behavior
collapsed across the first 30 min of the tests.
Results
Stable meth self-administration
Fifty rats acquired the self-administration task; four rats
were removed from the study as they displayed >15 %
infusion variability between the last two training sessions
(i.e., days 13 and 14); three rats died after a self-
administration session. An additional 3 rats were removed
due to failure to maintain stable self-administration
behavior during periods of intermittent self-administration
(i.e., responding for two consecutive days fell below 50 % of
the number of reinforcements received on day 14 of self-
administration). Of the 40 rats that completed the study,
there were no differences for active lever pressing (p=0.89;
one statistical outlier removed), inactive lever pressing
(p=0.23; three statistical outliers removed), or infusions
(p=0.76; one statistical outlier removed) for days 11–14
(paired t-test; Figure 2A).
Meth-seeking behavior: cue reactivity
A within-subjects design was used wherein each rat was
tested with three doses (randomized) of either the antag-
onist (SDZ; n = 11), inverse agonist (SB206; n = 8) and
the respective vehicles. Similarly, a within-subjects de-
sign was used to test for antagonist/inverse agonist inter-
actions with 3.0 mg/kg SB242 vs. 10.0 (n = 11) and
5.0 mg/kg (n = 10) SB206, and respective vehicles. There
were no significant differences among rats assigned to
SDZ (treatment group 1), SB206 (treatment group 2), or
interaction studies (treatment groups 3 and 4) for active
or inactive lever pressing during CR1 (ANOVA, p > 0.05;
data not shown). Additionally, active lever pressing com-
paring CR after vehicle pretreatment was not different
among the four treatment groups (ANOVA, p > 0.05;
data not shown). Self-administration behavior was not
altered by the interposed CR testing sessions; the first
and last day of intermittent self-administration were not
significantly different for active lever presses, inactive
lever presses, or infusions comparing day 16 and day 26
(paired t-test, p > 0.05; Figure 2B). In agreement with our
prior report validating consistent self-administration and
seeking [37], these data verify that behavior is persistent
throughout the paradigm.
Independent of the CR test number or pretreatment,
meth-seeking behavior occurred most intensely within
the first 15 min of CR testing (Figures 3 and 4) as previ-
ously reported [37]; by 30 min, levels emulated those
expressed on the inactive lever (data not shown). It is
also important to note that the number of lever presses
achieved during self-administration sessions are far
greater than the number during CR tests with a vehicle
Figure 2 Acquisition and maintenance of methamphetamine
self-administration. Illustrated is methamphetamine (meth)
self-administered as 0.1 mg/kg/0.1 ml on a fixed ratio (FR) 5
schedule of reinforcement. Forty rats completed the paradigm and
were tested for cue reactivity (CR). (A) Protocol days 8–14; rats
demonstrated stable self-administration. As measured by one-way
rmANOVA, no significant differences occurred across the last 3 days
of self-administration (days 12–14) for active lever presses
(F(3,37) = 8.95; two statistical outliers removed), inactive lever presses
(F(3,35) = 4.94; four statistical outliers removed), or infusions
(F(3,37) = 12.46; two statistical outliers removed). (B) Protocol days
16 and 26. Between each cue reactivity (CR) assessment, rats were
allowed to self-administer for two consecutive days on an FR5
schedule for 3 hr/day. Using paired t-tests, no differences occurred
between days 16 and 26 for active lever pressing (p = 0.89; one
statistical outlier removed), inactive lever pressing (p = 0.23; three
statistical outliers removed) or number of infusions received
(p = 0.76; one statistical outlier removed).
Figure 3 SB206 reduced reactivity to methamphetamine-
associated cues. Shown are active lever presses in 15 min intervals
for the first 30 min of cue reactivity (CR) testing as exhibited by rats
that completed dose–response assessments of SDZ Ser 082 (SDZ;
n = 10) and SB 206553 (SB206; n = 8). The x-axis legend refers to time
elapsed after treatment and immediately placing the subject into
the operant chamber; data represent total active lever presses
between 30-45 min and 45-60 min after treatment. One statistical
outlier was removed from the SDZ treatment group. (A) SDZ had no
effect on active lever pressing at any dose tested (two-way
rmANOVA). (B) SB206 significantly decreased active lever presses in
the first 15 min of testing at 1.0, 5.0, and 10.0 mg/kg (*p < 0.05
comparing vehicle vs. 1.0 and 5.0 mg/kg SB206; ***p < 0.001
comparing vehicle vs. 10.0 mg/kg SB206; Newman-Keuls post-hoc).
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during CR tests are not reinforced with meth and ii)
self-administration sessions are 3 hrs long whereas CR
tests are shown in15min intervals.
SDZ, the 5-HT2C antagonist, had no effect on number
of active (Figure 3A) or inactive lever pressing (data not
shown) at any dose tested. Two-way rmANOVA com-
paring active lever pressing revealed no significant
Treatment effect (F(3,36) = 0.81), a significant Time effect
(F(1,36) = 97.57), and no Treatment x Time interaction
(F(3,36) = 0.49). In contrast, administration of the 5-HT2C
inverse agonist SB206 attenuated active lever pressing in
the first 15 min at all doses tested (Figure 3B) resultingin an approximately 25 %, 50 %, and 95 % reduction in
active lever pressing by 1.0, 5.0, and 10.0 mg/kg, respect-
ively. Two-way rmANOVA revealed a significant effect
of Treatment (F(3,24) = 5.97) and Time (F(1,24) = 34.70),
and a Treatment x Time interaction (F(3,24) = 5.80). In-
active lever pressing was attenuated by approximately 60,
80, and 100 % for 1.0, 5.0, and 10.0 mg/kg SB206, re-
spectively, in the first 15 min of testing (data not shown).
While the percentage change in inactive lever pressing
appears dramatic, this only corresponds to approximately
2, 3, and 4 fewer inactive lever presses by 1.0, 5.0, and
10.0 mg/kg, respectively.
Similar to the effects seen with SDZ, 3.0 mg/kg of
SB242 (also a 5-HT2C receptor antagonist) had no effect
on active (Figure 4) or inactive (data not shown) lever
pressing when administered alone. Pretreatment with
3.0 mg/kg SB242 15 min prior to administration of 10.0
Table 2 Effects of SDZ Ser 082 and SB 206553 on motor
activity
Horizontal Activity Total Distance Vertical Activity
Vehicle 727± 85 189 ± 66 46 ± 10
1.0 mg/kg SDZ 572± 164 182 ± 65 88 ± 32
Vehicle 634± 66 186 ± 63 37 ± 14
5.0 mg/kg SB206 564± 132 107 ± 34 9± 3
Vehicle 379± 97 82 ± 42 32 ± 11
10.0 mg/kg SB206 453± 41 132 ± 30 11 ± 5
Rats that had undergone repeated cue reactivity testing were withdrawn from
methamphetamine and assessed for motor effects after pretreatment with
1.0 mg/kg SDZ Ser 082 (SDZ; 5-HT2C receptor antagonist), 5.0 mg/kg SB
206553 (SB206; putative 5-HT2C receptor inverse agonist), 10.0 mg/kg SB206
and respective vehicles. Serotonin2C receptor antagonism and inverse agonism
had no effect on motor activity.
Figure 4 Attenuation of active lever pressing by SB206 was not
reversed by the 5-HT2C antagonist SB242. Shown are active lever
presses in 15 min intervals for the first 30 min of cue reactivity (CR)
testing from rats that completed interaction studies with 3.0 mg/kg
SB 242084 (SB242) vs. 10.0 mg/kg SB 206553 (SB206; n = 11) or
5.0 mg/kg SB206 (n = 9; one statistical outlier removed). Rats were
tested after a pretreatment of vehicle or 3.0 mg/kg SB242, and
vehicle, 5.0, or 10.0 mg/kg SB206. The x-axis legend refers to time
elapsed after treatment and immediately placing the subject into
the operant chamber; data represent total active lever presses
between 30-45 min and 45-60 min after treatment. (A) 5-HT2C
antagonism with 3.0 mg/kg SB242 had no effect on CR when
administered alone and did not block the effects of 10.0 mg/kg
SB206. SB206 significantly decreased active lever presses in the first
15 min of testing (***p< 0.001; Newman-Keuls comparing veh/veh
vs. 10.0 mg/kg SB206) and significance was retained even following
pretreatment with SB242 (***p < 0.001; comparing veh/veh vs.
SB242/SB206). (B) 5-HT2C antagonism with 3.0 mg/kg SB242 had no
effect on active lever pressing when administered alone and did not
block the effects of 5.0 mg/kg SB206. SB206 significantly decreased
active lever presses in the first 15 min of testing (**p < 0.01;
Newman-Keuls comparing veh/veh vs. 5.0 mg/kg SB206) and
significance was retained following pretreatment with SB242
(***p < 0.001 comparing veh/veh vs. SB242/SB206).
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SB206-induced suppression of active (Figure 4) and
inactive (data not shown) lever pressing. Two-way
rmANOVA revealed a significant Treatment effect
(F(3,40) = 6.04), Time effect (F(1,40) = 21.97), and Treatment
x Time interaction (F(3,40) = 7.36) comparing the effects
of 3.0 mg/kg SB242 and 10.0 mg/kg SB206 as well as a
significant Treatment effect (F(3,32) = 4.90), Time effect
(F(1,32) = 36.71), and Treatment x Time interaction
(F(3,32) = 5.151) comparing the effects of 3.0 mg/kg SB242
and 5.0 mg/kg SB206. Our antagonist data are consistent
with the inability of 5-HT2C antagonism to alter cue-induced reinstatement of cocaine-seeking [5,7]. However,
because the SB242 did not prevent SB206-induced
decreases in lever pressing, it is unclear whether SB206
effects are 5-HT2C dependent.Normal exploratory and meth-evoked motor activity
To assess the ability for the 5-HT2C ligands to impact
non-operant-related motor activity, SDZ and SB206
were tested for motor effects in the absence and pres-
ence of meth. In the absence of meth, neither the SDZ
(1.0 mg/kg) nor SB206 (5.0 or 10.0 mg/kg) altered motor
activity (Table 2). SDZ (1.0 mg/kg) had no effect on
meth-evoked motor activity, (Table 3). Likewise, the
lower dose of 5.0 mg/kg SB206, which was sufficient to
attenuate meth-seeking, had no effect on meth-evoked
Table 3 Meth-evoked motor activity: SDZ Ser 082 and SB 206553 effects
Horizontal Activity Total Distance Vertical Activity Stereotypy Count
Vehicle 8797 ± 738 3832± 336 1142± 122 477 ± 33
1.0 mg/kg SDZ 8598± 858 3723± 392 996 ± 190 460 ± 29
Vehicle 7448 ± 1025 3113± 444 797 ± 141 446 ± 29
5.0 mg/kg SB206 9067± 711 4326± 572 594 ± 120 471 ± 18
Vehicle 8429 ± 1133 3705± 692 1124± 201 471 ± 26
10.0 mg/kg SB206 6448± 1276 2245± 499 398 ± 91** 394 ± 58
Rats that had undergone repeated cue reactivity testing were withdrawn from methamphetamine and assessed for methamphetamine-evoked (1.0 mg/kg) motor
effects after a 30 min pretreatment with 1.0 mg/kg SDZ Ser 082 (SDZ; 5-HT2C receptor antagonist), 5.0 mg/kg SB 206553 (SB206; putative 5-HT2C receptor inverse
agonist), 10.0 mg/kg SB206 and respective vehicles. Serotonin2C receptor antagonism had no effect on methamphetamine-evoked motor activity whereas inverse
agonism with 10.0 mg/kg SB206 significantly attenuated vertical activity (paired t-test; **p < 0.01).
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only significantly attenuated meth-evoked vertical
activity.
Discussion
SB 206553 attenuates methamphetamine-seeking
Results from the current study are the first to investigate
the role of 5-HT2C receptor activity in meth-mediated
behaviors and the first to test SB206 in a rodent model
of addiction. We revealed that the putative inverse agon-
ist robustly and dose-dependently attenuated meth-
seeking without impacting exploratory motor activity at
5.0 mg/kg and 10.0 mg/kg. The 5-HT2C antagonists had
no effect on either meth-seeking or meth-induced motor
activity. These results suggest that our prior work with
mirtazapine may reflect the ability of mirtazapine to act
as an inverse agonist, not as a 5-HT2C antagonist.
The finding that the antagonist SB242 did not attenu-
ate the effects of the inverse agonist SB206 was unex-
pected, and raised the question regarding the receptor
selectivity of SB206. SB206 has high affinity for both the
5-HT2C and 5-HT2B receptors (pKi = 8.5 and pKi = 8.26,
respectively in HEK-293 or CHO-K1 cells expressing
human recombinant 5-HT2C or 5-HT2B receptors;
Table 1) [45] with 100 fold or greater selectivity over
other receptor targets including 5-HT2A receptors [46].
In the current study, SB206 may antagonize 5-HT2B
receptors, which are known to regulate behavioral and
DA-enhancing effects of amphetamine [47]. However,
the increase in accumbal DA seen with 5.0 mg/kg SB206
is not altered with coadministration of the 5-HT2B an-
tagonist LY 266097 indicating that 5.0 mg/kg SB206
does not substantially antagonize 5-HT2B receptors [47].
Antagonism of 5-HT2A receptors are a third 5-HT re-
ceptor that may be contributing to our findings. 5-HT2A
antagonism with M100907 attenuates cue-induced re-
instatement of cocaine-seeking [48] and meth-seeking
(unpublished data). As mentioned above, SB206 demon-
strates 100 fold selectivity over the 5-HT2A receptor.
5-HT2A antagonism by SB206, particularly at 10.0 mg/kg,
is plausible but unlikely at 1.0 and 5.0 mg/kg, foramphetamine-evoked DA concentrations in the nucleus
accumbens and striatum are attenuated by 5-HT2A
antagonism but 5.0 mg/kg SB206 has no effect [49]
suggesting that at this dose, SB206 does not act on
5-HT2A receptors. Additionally, 5.0 mg/kg SB206 and
5-HT2A antagonism with SR 46349B have oppositional
effects demonstrated by striatal [11 C]raclopride binding
lending further evidence to the selectivity of SB206 for
5-HT2C over 5-HT2A receptors [50]. Taken together, the
available in vivo data suggests that SB206 does not
antagonize 5-HT2A receptors at 5.0 mg/kg.
SB206 may also act as a positive allosteric modulator
of the α7 nicotinic acetylcholine receptor with an EC50
of 1.5 μM for potentiation of responses evoked in
GH4C1 cells by EC20 nicotine [51]. Dunlop et al., find
that 3, 10, and 30 mg/kg SB206 reverses MK-801-
induced deficits in prepulse inhibition, a classical model
of schizophrenia, but only confirm actions as a positive
allosteric modulator using a nicotinic antagonist against
10.0 mg/kg SB206. It is unclear whether lower doses,
such as 1.0 and 5.0 mg/kg SB206, would also act as a
positive allosteric modulator at α7 nicotinic receptors.
Consistent with our findings, antagonism of α7 nicotinic
receptors in the ventral tegmental area attenuates the
reward-facilitating effect of cocaine [52] whereas nico-
tine administration attenuates reinstatement of meth-
seeking [53]. The role of α7 nicotinic receptors and in
particular, positive allosteric modulation of this receptor,
in meth abuse is understudied. Future investigation are
needed to determine if this receptor is engaged by
SB206 in the dose range tested before actions at the α7
receptor can be ruled out.
Debating receptor specificity based on our findings is
difficult; however, it is important to note that a prior re-
port showed that 1.0 mg/kg SB242 attenuates 5.0 mg/kg
SB206-induced increases in striatal and accumbal DA
[8]. Reasons why Spampinato and colleagues were able
to antagonize SB206 effects and we were not may relate
to the treatment history of rodent subjects. In the afore-
mentioned neurochemical study [8], subjects were
stimulant naïve, halothane anesthetized rats. In our
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istration. This chronic meth history may have modified
the 5-HT2C system, for we have observed a functionally
upregulated response to systemic 5-HT2A/C receptor
agonism in the ventral pallidum of rats chronically admi-
nistered meth [54]. Repeated meth administration may
result in changes in mRNA editing profiles (and thus,
levels of constitutive activity). Proof of concept for this
hypothesis is seen with studies on stress, antidepressant,
and antipsychotic administration where mRNA editing
of the 5-HT2C receptor is altered [55-58]. In addition to
changing constitutive activity, mRNA editing of the
5-HT2C receptor also alters the binding affinity of ligands
whereby increased editing most often results in
decreased agonist affinity for the receptor with enhanced
or no effect on antagonists and inverse agonist binding
affinity [16-18,20]. It is unknown how editing patterns
affect the affinities of SB206 and SB242. Thus, the inabil-
ity of SB242 to augment the effects of SB206 on CR may
reflect changes in affinity for constitutively active iso-
forms and/or in the allosteric constant (i.e., an index of
the concentration of constitutively active vs. non-
constitutively active receptors). Unfortunately ex vivo
binding studies, which would greatly facilitate our stud-
ies, are hampered by a lack of available tritiated ligands
with 5-HT2C specificity. While future studies are needed
to explore the mechanism of action for SB206 and deter-
mine receptor specificity in vivo, we speculate that des-
pite a lack of antagonism by SB242, 5-HT2C receptors
may still be involved. Moreover, continued study is ne-
cessary to determine the effects of 5-HT2C receptor
ligands on neuron function; to provide further insights
our laboratory is conducting patch clamp studies in
ex vivo slice preparations to determine the effects of
5-HT2C ligands, including SB206, on neurophysiology.
SB 206553, but not SDZ Ser 082, attenuates
methamphetamine-evoked motor activity
Acute antagonism of 5-HT2C receptors enhances the
motor effects of acute cocaine administration; however,
this enhancement is lost in rats that are motorically sen-
sitized by repeated injections of cocaine [40]. This is
comparable to our current findings wherein rats with a
history of meth self-administration, 5-HT2C antagonism
did not alter meth-evoked motor activity in rats. A sin-
gle study testing SB206 on cocaine-evoked motor activ-
ity finds an attenuation of cocaine-evoked motor activity
by 1.0 mg/kg SB206 but a potentiation with 4.0 mg/kg
[59]; however, this was an acute study with a single injec-
tion of cocaine making it difficult to compare with the
current investigations using meth self-administration. In
rats with a history of meth self-administration, only
meth-evoked vertical activity was attenuated by
10.0 mg/kg SB206. Both our findings and [59] are inagreement in that SB206 does not alter normal explora-
tory motor behavior suggesting that SB206 is not sedating;
differences in our study and [59] regarding the ability to
augment psychostimulant-evoked motor activity may re-
flect behavioral differences consequent to meth-induced
plasticity. This hypothesis is supported by [40] and our
current findings wherein 5-HT2C antagonism fails to aug-
ment cocaine-evoked and meth-evoked motor activity in
rats with a history of repeated cocaine [40] or meth
administration.
SB 206553 decreases inactive lever pressing
Antagonists had no effect, whereas SB206 attenuated in-
active lever pressing. Mirtazapine, also an inverse agonist
at the 5-HT2C receptor [35,36], similarly attenuates in-
active lever pressing in a cue-induced reinstatement
paradigm without effecting non-operant related motor
activity in a small animal activity chamber in rats with a
history of meth self-administration or rotorod perform-
ance in naïve rats [37]. Moreover, in naïve rats, adminis-
tration of 1, 3, and 4 mg/kg SB206 has no effect on
motor activity (measured in activity chambers) [59]. A
similar pattern is found for GABAB receptor activation.
The GABAB agonist (CGP44542) decreases inactive lever
pressing in an operant task [60], yet has no effect on
performance in an intracranial self-stimulation proced-
ure [61]. In summary, as SB206 had no effect on motor
activity in in rats with a meth history (current report) or
in naïve rats [59], and that mirtazapine, also an inverse
agonist at 5-HT2C receptors [35,36], does not impair
motor activity in naïve rats [37], we considered that
decreased lever pressing of both active and inactive
levers seen in the current study was not a consequence
of decreased motor activity. Accordingly, we propose
that SB206 blunted the salience of the levers, both active
and inactive, rather than impairing the ability of the rats
to perform the operant task. This interpretation is sup-
ported by our prior demonstration that significance of
meth-associated context cues are reduced by mirtazapine
[31]. Additional studies aimed at exploring the effect of
SB206 on non-drug reinforced behaviors may advance
this hypothesis; however, as 5-HT2C receptors regulate
food intake [6,62,63] as well as intracranial self-
stimulation behavior [64,65], such evaluations may chal-
lenging to conduct and difficult to interpret.
Conclusions
The presented findings are the first to explore the
effects of 5-HT2C antagonists and putative inverse
agonist, SB206, on meth-seeking and meth-induced
motor activity. Serotonin2C antagonism had no effect
on meth-seeking or motor activity (in the presence or
absence of meth); in contrast, SB206, attenuated meth-
seeking. This effect was selective, as SB206 agonist did
Graves and Napier BMC Neuroscience 2012, 13:65 Page 9 of 10
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reduced one motor parameter evoked by meth (i.e., ver-
tical activity). There is a growing interest in assessing
the role of constitutively active 5-HT2C receptors in vivo.
It is currently unclear whether SB206 elicits the
observed effects via 5-HT2C receptor inverse agonism;
nonetheless, based on the dramatic reduction in seeking
behavior, further investigation of this compound is mer-
ited as well as continued study of 5-HT2C regulation of
psychostimulant-mediated behaviors.
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